-
Something wrong with this record ?
Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection
V. Kolek, S. Losse, J. Kultan, P. Jakubec, Z. Jaromir, M. Sova, M. Szkorupa, Č. Neoral, J. Škarda, T. Tichý, Z. Kolář,
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV16-32318A
MZ0
CEP Register
- MeSH
- Chemotherapy, Adjuvant * methods statistics & numerical data MeSH
- Survival Analysis MeSH
- Cisplatin therapeutic use MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Interdisciplinary Communication MeSH
- Lung Neoplasms * drug therapy mortality pathology therapy MeSH
- Carcinoma, Non-Small-Cell Lung * drug therapy mortality pathology surgery MeSH
- Pneumonectomy * methods statistics & numerical data MeSH
- Antineoplastic Agents therapeutic use MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Drug Utilization statistics & numerical data MeSH
- Neoplasm Staging MeSH
- Vinorelbine therapeutic use MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
OBJECTIVES: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after complete tumor resection. Utilization and outcome of AC in routine practice is described in a few studies, with non-conclusive results. MATERIALS AND METHODS: This retrospective study included consecutive patients with NSCLC who underwent curative-intent surgery. Data of AC uptake in stages IB (tumor of ≥4 cm in diameter), II, and IIIA, and reasons of AC omission were evaluated according to medical records. Mortality risk among patients treated with surgery (only) and different types of AC in routine practice was compared. RESULTS: AC was applied to 79% of patients with stages IB (tumor of ≥4 cm in diameter), II, and IIIA, and was associated with an improved median of overall survival (HR = 0.69; 95% CI = 0.44-1.06). Significantly longer survival was achieved in the sub-group treated with platinum and oral vinorelbine (HR = 0.575, 95% CI = 0.339-0.974), and the longest survival was among patients treated with oral vinorelbine and cisplatin (HR = 0.371, 95% CI = 0.168-0.820). CONCLUSIONS: AC utilization should be based on co-operation between surgeons, pneumo-oncologists, and patients. Rational use of AC offers better survival in routine practice.
b Department of Surgery University Hospital Olomouc Olomouc Czech Republic
c Department of Molecular Pathology Palacky University Olomouc Czech Republic
Department of Respiratory Medicine University Hospital Olomouc Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045408
- 003
- CZ-PrNML
- 005
- 20220505092740.0
- 007
- ta
- 008
- 200109s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/03007995.2018.1490254 $2 doi
- 035 __
- $a (PubMed)29912578
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kolek, Vítězslav $u a Department of Respiratory Medicine , University Hospital Olomouc , Olomouc , Czech Republic.
- 245 10
- $a Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection / $c V. Kolek, S. Losse, J. Kultan, P. Jakubec, Z. Jaromir, M. Sova, M. Szkorupa, Č. Neoral, J. Škarda, T. Tichý, Z. Kolář,
- 520 9_
- $a OBJECTIVES: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after complete tumor resection. Utilization and outcome of AC in routine practice is described in a few studies, with non-conclusive results. MATERIALS AND METHODS: This retrospective study included consecutive patients with NSCLC who underwent curative-intent surgery. Data of AC uptake in stages IB (tumor of ≥4 cm in diameter), II, and IIIA, and reasons of AC omission were evaluated according to medical records. Mortality risk among patients treated with surgery (only) and different types of AC in routine practice was compared. RESULTS: AC was applied to 79% of patients with stages IB (tumor of ≥4 cm in diameter), II, and IIIA, and was associated with an improved median of overall survival (HR = 0.69; 95% CI = 0.44-1.06). Significantly longer survival was achieved in the sub-group treated with platinum and oral vinorelbine (HR = 0.575, 95% CI = 0.339-0.974), and the longest survival was among patients treated with oral vinorelbine and cisplatin (HR = 0.371, 95% CI = 0.168-0.820). CONCLUSIONS: AC utilization should be based on co-operation between surgeons, pneumo-oncologists, and patients. Rational use of AC offers better survival in routine practice.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 12
- $a nemalobuněčný karcinom plic $x farmakoterapie $x mortalita $x patologie $x chirurgie $7 D002289
- 650 12
- $a adjuvantní chemoterapie $x metody $x statistika a číselné údaje $7 D017024
- 650 _2
- $a cisplatina $x terapeutické užití $7 D002945
- 650 _2
- $a spotřeba léčiv $x statistika a číselné údaje $7 D004363
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mezioborová komunikace $7 D033183
- 650 12
- $a nádory plic $x farmakoterapie $x mortalita $x patologie $x terapie $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 12
- $a pneumektomie $x metody $x statistika a číselné údaje $7 D011013
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a vinorelbin $x terapeutické užití $7 D000077235
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Losse, Stanislav $u a Department of Respiratory Medicine , University Hospital Olomouc , Olomouc , Czech Republic. $7 pna2017972504
- 700 1_
- $a Kultan, Juraj $u a Department of Respiratory Medicine , University Hospital Olomouc , Olomouc , Czech Republic.
- 700 1_
- $a Jakubec, Petr $u a Department of Respiratory Medicine , University Hospital Olomouc , Olomouc , Czech Republic.
- 700 1_
- $a Jaromir, Zatloukal $u a Department of Respiratory Medicine , University Hospital Olomouc , Olomouc , Czech Republic.
- 700 1_
- $a Sova, Milan, $u a Department of Respiratory Medicine , University Hospital Olomouc , Olomouc , Czech Republic. $d 1985- $7 xx0140833
- 700 1_
- $a Szkorupa, Marek $u b Department of Surgery , University Hospital Olomouc , Olomouc , Czech Republic.
- 700 1_
- $a Neoral, Čestmír $u b Department of Surgery , University Hospital Olomouc , Olomouc , Czech Republic.
- 700 1_
- $a Škarda, Josef $u c Department of Molecular Pathology , Palacky University , Olomouc , Czech Republic.
- 700 1_
- $a Tichý, Tomáš $u c Department of Molecular Pathology , Palacky University , Olomouc , Czech Republic.
- 700 1_
- $a Kolář, Zdeněk $u c Department of Molecular Pathology , Palacky University , Olomouc , Czech Republic.
- 773 0_
- $w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 34, č. 9 (2018), s. 1687-1694
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29912578 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20220505092734 $b ABA008
- 999 __
- $a ok $b bmc $g 1483677 $s 1084081
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 34 $c 9 $d 1687-1694 $e 20180709 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
- GRA __
- $a NV16-32318A $p MZ0
- LZP __
- $a Pubmed-20200109
